血管紧张素轴拮抗剂增加二氢吡啶类钙通道阻滞剂中毒血流动力学不稳的发生率
这项回顾性研究纳入澳大利亚新南威尔士毒物信息中心及3个毒理学单位2016年1月至2019年6月报告的100例>14岁二氢吡啶类过量患者,其中68例为二氢吡啶类与血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂混合过量,32例为单用二氢吡啶类过量。混合组最低中位平均动脉压更低(62 vs 75 mmHg,p<0.001),发生低血压(OR 4.5,95%CI:1.7-11.9)和心动过缓(OR 8.8,95%CI:1.1-70)更频繁。多变量分析显示混合过量组最低收缩压较单用组低11.5 mmHg(95%CI:4.9-18.1),且混合组更多接受静脉输液(OR 5.7,95%CI:1.8-18.6)及解毒剂和/或血管升压药(OR 2.9,95%CI:1.004-8.6)。
要点
- 二氢吡啶类与血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂混合过量者最低中位平均动脉压为62 mmHg,单用二氢吡啶类者为75 mmHg(p<0.001)。
- 混合过量组发生低血压的OR为4.5(95%CI:1.7-11.9),发生心动过缓的OR为8.8(95%CI:1.1-70)。
- 多变量分析中混合过量组最低收缩压较单用组低11.5 mmHg(95%CI:4.9-18.1)。
- 混合过量组接受静脉输液的OR为5.7(95%CI:1.8-18.6),接受解毒剂和/或血管升压药的OR为2.9(95%CI:1.004-8.6)。
- 每增加10个限定日剂量,最低收缩压降低2.3 mmHg(95%CI:1.1-3.5);年龄每增加10岁,最低收缩压升高2.2 mmHg(95%CI:0.3-4.2)。
适用人群与场景
- 纳入2016年1月至2019年6月报告至澳大利亚新南威尔士毒物信息中心及3个毒理学单位的年龄>14岁二氢吡啶类(氨氯地平、非洛地平、乐卡地平、硝苯地平)过量患者。
- 排除与去甲二氢吡啶类钙通道阻滞剂、α受体阻滞剂和β受体阻滞剂同时过量的患者。
红旗征与不能漏的情况
- 二氢吡啶类与血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂混合过量者低血压(OR 4.5,95%CI:1.7-11.9)和心动过缓(OR 8.8,95%CI:1.1-70)风险更高,需警惕血流动力学不稳定。
- 混合过量组更可能需要静脉输液(OR 5.7,95%CI:1.8-18.6)及解毒剂和/或血管升压药(OR 2.9,95%CI:1.004-8.6)。
研究设计与关键结果
- 回顾性研究纳入100例患者,其中68例为二氢吡啶类与血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂混合过量,32例为单用二氢吡啶类过量。
- 混合组最低中位平均动脉压为62 mmHg,单用组为75 mmHg(p<0.001)。
- 混合组低血压OR 4.5(95%CI:1.7-11.9),心动过缓OR 8.8(95%CI:1.1-70)。
- 多变量分析显示混合过量组最低收缩压较单用组低11.5 mmHg(95%CI:4.9-18.1)。
- 每增加10个限定日剂量,最低收缩压降低2.3 mmHg(95%CI:1.1-3.5);年龄每增加10岁,最低收缩压升高2.2 mmHg(95%CI:0.3-4.2)。
- 混合组接受静脉输液OR 5.7(95%CI:1.8-18.6),接受解毒剂和/或血管升压药OR 2.9(95%CI:1.004-8.6)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊接诊二氢吡啶类过量患者时,应询问是否同时服用血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂,混合过量者可能更易出现低血压和心动过缓并需要更多血流动力学支持。
- 对二氢吡啶类与血管紧张素Ⅱ受体拮抗剂或血管紧张素转换酶抑制剂混合过量者,应更积极监测血压和心率,并准备静脉输液及解毒剂和/或血管升压药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Amlodipine, a dihydropyridine calcium channel blocker (CCB), is the leading cause of cardiovascular drug-related overdose deaths in the USA. In contrast, angiotensin-II receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) cause minimal toxicity in overdose. ACEIs/ARBs are often combined with dihydropyridines in hypertension treatment. Co-ingested ARBs/ACEIs may significantly contribute to the toxicity of dihydropyridine, but this has not been investigated.
OBJECTIVE: To investigate the clinical outcomes from dihydropyridine overdoses with ARBs/ACEIs versus dihydropyridine overdoses alone.
METHODS: This was a retrospective study of patients reported to the New South Wales Poisons Information Centre (NSW PIC) and 3 toxicology units (Jan 2016 to Jun 2019) in Australia. Patients >14 years who took an overdose of dihydropyridines (amlodipine, felodipine, lercanidipine, nifedipine) were included. Concurrent overdoses with non-dihydropyridine CCBs, alpha-blockers and beta-blockers were excluded. Patient demographics, drugs exposure details, serial vital signs, treatments and outcome were collected.
RESULTS: There were 100 patients. 68 took mixed overdoses of dihydropyridines with ARBs/ACEIs and 32 took single overdoses of dihydropyridines without ARBs/ACEIs. The mixed group had lower median nadir mean arterial pressures (62 vs 75 mmHg, p < 0.001), more frequently had hypotension (OR 4.5, 95%CI: 1.7-11.9) or bradycardia (OR 8.8, 95%CI: 1.1-70). Multivariable analysis indicated the mixed overdoses had an 11.5 mmHg (95%CI: 4.9-18.1) lower minimum systolic blood pressure (SBP) compared with the single group; other factors associated with a lower minimum SBP were higher doses [2.3 mmHg (95%CI: 1.1-3.5) lower per 10 defined daily doses] and younger age [2.2 mmHg (95%CI: 0.3-4.2) higher per decade]. A larger proportion of the mixed ingestion group received intravenous fluids (OR 5.7, 95%CI: 1.8-18.6) and antidotes and/or vasopressors (OR 2.9, 95%CI: 1.004-8.6).
CONCLUSION: Combined overdoses of dihydropyridines with ARBs/ACEIs caused more significant hypotension and required more haemodynamic support than overdoses of dihydropyridines alone.
参考来源
- Huang J, Buckley NA, Isoardi KZ, et al. Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning. Clin Toxicol (Phila). 2020. PMID: 33021397. doi:10.1080/15563650.2020.1826504
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。